Oncology

The FDA approved belzutifan, the first oral treatment for pheochromocytoma and paraganglioma, offering a new treatment pathway for patients with these rare tumors.

Effectively communicating research findings to patients, health care professionals, and policy payers is necessary for engagement.

This new generic will impact both oncology and community pharmacists.

Explore the latest insights on emerging antibody drug conjugates for HER2 breast cancer and real-world management strategies.

During a panel discussion, 3 experts highlighted ways health care professionals and researchers can help provide patient-centered care.

The new at-home test aims to increase comfort and screening timeliness through a more accessible method.

Abemaciclib and ribociclib have various risks and benefits in treating early breast cancer, highlighting the importance of patient-provider communication.

With the FDA approval, avutometinib/defactinib is now the first and only FDA-approved treatment for patients with recurrent low-grade serous ovarian cancer (LGSOC).

Pharmacists can educate patients on nonpharmacologic strategies that help improve survival outcomes.

Trastuzumab deruxtecan was safe and efficacious prior to treatment with paclitaxel, trastuzumab, and pertuzumab.

The time frame concept is an underappreciated through line in most planning efforts.

The agent targets B7-H3, a commonly overexpressed protein in diffuse intrinsic pontine glioma (DIPG).

One dose of the vaccine compared with 2 may help increase global HPV vaccine uptake.

This screening method can help empower patients to better manage their health and seek additional care.

Abigail Thomas, PharmD, and Lee A. Kral, PharmD, discuss the evolving role of psilocybin-assisted therapy in palliative care, highlighting current evidence, safety concerns, and how pharmacists can guide patient selection, manage drug interactions, and support education as the therapy moves closer to clinical use.

This installment of our series on ADCs and HER2 breast cancer offers key insights about novel agents in clinical trials and management of ADC therapies.

The salvage therapy led to an 80% overall response rate in patients with relapsed/refractory multiple myeloma.

Currently, the treatment is undergoing evaluation in a 3-part clinical trial to determine its safety, efficacy, and pharmacokinetics in patients with recurrent advanced/metastatic cancers.

Despite benefits for reducing drug costs, community oncology practices face the unintended consequences of the IRA.

Jonas Congelli, RPh, discusses how limited distribution networks and medically integrated pharmacies can improve access, continuity, and quality of oncology care—particularly in underserved areas—while addressing systemic barriers posed by traditional distribution models and pharmacy benefit managers.

Ravi Parikh, MD, MPP, FACP, discusses how artificial intelligence is transforming oncology pharmacy by accelerating drug development, enhancing clinical decision-making, supporting value-based care, and raising critical questions about ethics, regulation, and data integrity.

Liposomal annamycin demonstrates broad synergistic activity with multiple FDA-approved chemotherapies across hematologic and solid tumors in preclinical models, offering a promising and safer combination strategy for resistant and high-risk cancers.

Douglas Adkins, MD shares key data and findings from the phase 3 KEYNOTE-689 study.

Explore the latest advancements in treating transplant-ineligible multiple myeloma, highlighting new therapies and clinical trial outcomes for improved patient care.

Sasha Watson, PharmD, BCOP, discusses the emerging role of circulating tumor DNA (ctDNA) in colon cancer, highlighting its potential to enhance precision oncology by improving early detection, guiding adjuvant therapy decisions, and monitoring disease recurrence and treatment resistance.

Updates on April 30, 2025, introduce changes to treatment regimens, sequencing flexibility, febrile neutropenia risk assessments, and drug-specific safety and supportive care guidance.

A phase 1b study demonstrated that continuous subcutaneous infusion of low-dose lenalidomide in patients with relapsed or refractory (R/R) multiple myeloma achieved promising efficacy with significantly reduced hematologic toxicity compared to conventional oral dosing.